|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McCracken M, Olsen M, Chen MS Jr, et al:
Cancer incidence, mortality, and associated risk factors among
Asian Americans of Chinese, Filipino, Vietnamese, Korean, and
Japanese ethnicities. CA Cancer J Clin. 57:190–205. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Erridge SC, Moller H, Price A and Brewster
D: International comparisons of survival from lung cancer: pitfalls
and warnings. Nat Clin Pract Oncol. 4:570–577. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ramalingam S and Belani C: Systemic
chemotherapy for advanced non-small cell lung cancer: recent
advances and future directions. Oncologist. 13(Suppl 1): 5–13.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Laskin JJ and Sandler AB: First-line
treatment for advanced non-small-cell lung cancer. Oncology
(Williston Park). 19:1671–1676. 2005.
|
|
6
|
Langer F, Helsberg K, Schütte WH and
Leschinger MI: Gemcitabine in the first line therapy of advanced
and metastatic non-small-cell lung carcinoma (NSCLC): review of the
results of phase III studies. Onkologie. 28(Suppl 1): 1–28.
2005.
|
|
7
|
Cucević B, Samarzija M, Baricević D, et
al: Gemcitabine in the first and second-line chemotherapy of
advanced non-small cell lung cancer. Coll Antropol. 29:583–588.
2005.
|
|
8
|
Natale R: A ten-year review of progress in
the treatment of non-small-cell lung cancer with gemcitabine. Lung
Cancer. 50:S2–S4. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lund B, Hansen OP, Theilade K, Hansen M
and Neijit JP: Phase II study of gemcitabine
(2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer
patients. J Natl Cancer Inst. 86:1530–1533. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Heinemann V: Gemcitabine: progress in the
treatment of pancreatic cancer. Oncology. 60:8–18. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee J, Tae N, Lee JJ, Kim T and Lee JH:
Eupatolide inhibits lipopolysaccharide-induced COX-2 and iNOS
expression in RAW264.7 cells by inducing proteasomal degradation of
TRAF6. Eur J Pharmacol. 636:173–180. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jin HZ, Lee D, Lee JH, et al: New
sesquiterpene dimers from Inula britannica inhibit NF-kappaB
activation and NO and TNF-alpha production in LPS-stimulated
RAW264.7 cells. Planta Med. 72:40–45. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu YP, Wen JK, Zheng B, Zhang DQ and Han
M: Acetylbritannilactone suppresses lipopolysaccharide-induced
vascular smooth muscle cell inflammatory response. Eur J Pharmacol.
577:28–34. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rafi MM, Bai NS, Chi-Tang-Ho, et al: A
sesquiterpenelactone from Inula britannica induces anti-tumor
effects dependent on Bcl-2 phosphorylation. Anticancer Res.
25:313–318. 2005.PubMed/NCBI
|
|
15
|
Bai N, Lai CS, He K, et al: Sesquiterpene
lactones from Inula britannica and their cytotoxic and apoptotic
effects on human cancer cell lines. J Nat Prod. 69:531–535. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pan MH, Chiou YS, Cheng AC, et al:
Involvement of MAPK, Bcl-2 family, cytochrome c, and caspases in
induction of apoptosis by 1,6-O,O-diacetylbritannilactone in human
leukemia cells. Mol Nutr Food Res. 51:229–238. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu S, Liu H, Yan W, et al: Studies on
1-O-acetylbritannilactone and its derivative,
(2-O-butyloxime-3-phenyl)-propionyl-1- O-acetylbritannilactone
ester. Bioorg Med Chem Lett. 14:1101–1104. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu S, Liu H, Yan W, et al: Design,
synthesis, and anti-tumor activity of
(2-O-alkyloxime-3-phenyl)-propionyl-1-O-acetylbritannilactone
esters. Bioorg Med Chem. 15:2783–2789. 2005. View Article : Google Scholar
|
|
19
|
Liu B, Han M, Sun RH, et al: ABL-N-induced
apoptosis in human breast cancer cells is partially mediated by
c-Jun NH2-terminal kinase activation. Breast Cancer Res. 12:R92010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Shi X, Fu Y, et al: Preparation
and determination of 1-O-acetylbritannilactone in Inula Britannica
L. Se Pu. 23:573–576. 2005.In Chinese.
|
|
21
|
Baltimore D and Beg AA: DNA-binding
proteins. A butterfly flutters by. Nature. 373:287–288. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gilmore TD, Koedood M, Piffat KA and White
DW: Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene.
13:1367–1378. 1996.PubMed/NCBI
|
|
23
|
Boise LH, Gottschalk AR, Quintáns J and
Thompson CB: Bcl-2 and Bcl-2-related proteins in apoptosis
regulation. Curr Top Microbiol Immunol. 200:107–121.
1995.PubMed/NCBI
|
|
24
|
Korsmeyer SJ, Shutter JR, Veis DJ, Merry
DE and Oltvai ZN: Bcl-2/Bax: a rheostat that regulates an
anti-oxidant pathway and cell death. Semin Cancer Biol. 4:327–332.
1993.PubMed/NCBI
|
|
25
|
Chao DT and Korsmeyer SJ: BCL-2 family:
regulators of cell death. Annu Rev Immunol. 16:395–419. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fahy BN, Schlieman MG, Mortenson MM,
Virudachalam S and Bold RJ: Targeting BCL-2 overexpression in
various human malignancies through NF-κB inhibition by the
proteasome inhibitor bortezomib. Cancer Chemother Pharmacol.
56:46–54. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rho JK, Choi YJ, Ryoo BY, et al: p53
enhances gefitinib-induced growth inhibition and apoptosis by
regulation of Fas in non-small cell lung cancer. Cancer Res.
67:1163–1169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shimizu M, Kondo M, Ito Y, et al: Soluble
Fas and Fas ligand provide new information on metastasis and
response to chemotherapy in SCLC patients. Cancer Detect Prev.
29:175–180. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun SY, Yue P, Hong WK and Lotan R:
Induction of Fas expression and augmentation of Fas/Fas
ligand-mediated apoptosis by the synthetic retinoid CD437 in human
lung cancer cells. Cancer Res. 60:6537–6543. 2000.PubMed/NCBI
|
